版本:
中国

BRIEF-Seattle Genetics, Bristol-Myers Squibb highlight interim phase 1/2 data

June 15 Bristol-Myers Squibb Co:

* Seattle Genetics and Bristol-Myers Squibb highlight interim phase 1/2 data evaluating combination of adcetris® (brentuximab vedotin) and opdivo® (nivolumab) in relapsed hodgkin lymphoma at the international conference on malignant lymphoma

* Bristol-Myers Squibb Co - combination data show 85 percent objective response rate and 63 percent complete response rate

* Bristol-Myers Squibb-‍data support recently initiated pivotal phase 3 clinical trial evaluating adcetris & opdivo combination in relapsed hodgkin lymphoma​

* Bristol-Myers Squibb- ‍forty-five percent of patients had primary refractory disease, 55 percent progressed after responding to frontline therapy in study​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐